Background and Purpose-The purpose of the present study was to develop and rate performance measures for hospital-based acute ischemic stroke. Methods-A national multidisciplinary panel of 16 individuals (2 stroke specialists, 2 general neurologists, 2 internists, 2 neuroscience nurses, 2 stroke advocacy organization representatives, 1 stroke rehabilitationist, 1 family practitioner, 1 emergency room physician, 1 neuroradiologist, 1 managed care organization director, and 1 hospital association representative) from 10 medical societies or lay organizations assisted in the development of 44 potential stroke performance measures. We developed evidence summaries for each of the performance measures and graded the level of evidence associated with each measure. The panel received a summary of the literature pertaining to each measure and rated the measures by use of a modified Delphi approach for 6 dimensions of quality, including validity of evidence, feasibility, impact on outcomes, room for improvement, plausibility, and an overall rating (little reason to do, could do, should do, and must do). Results-Highly rated and agreed on performance measures for the overall rating include warfarin in atrial fibrillation, antithrombotics on hospital discharge, carotid imaging in appropriate patients, and use of stroke units. Additional measures notable for high agreement were heparins for deep-vein thrombosis prophylaxis and use of a stroke protocol.
Q uality of health care varies throughout the United States and frequently does not meet professional standards. 1 Patients at risk for or who have had a stroke often do not receive medical care consistent with current evidence-based standards. 2 For example, only 57% of patients with hypertension and 25% to 64% of patients with hyperlipidemia receive proper treatment. 3 In addition, only 18% of hospitals in 1 state had an organized stroke unit. 4 On a national scale, the percentage of hospitalized patients with a stroke or transient ischemic attack discharged on an antithrombotic agent ranged from 72% to 90%, whereas the percentage of appropriate patients in atrial fibrillation discharged on warfarin ranged from 31% to 64%. 5 Despite this growing body of data, we still have relatively little information as to the extent, variation, and cause of the stroke evidence-practice gap.
See Editorial Comment, page 2073
One reason that we know so little about what is happening to stroke patients during the course of receiving medical care is that we lack a standard set of clinical measures for providers, health systems, and payers to use to monitor the quality of care. However, new initiatives are underway to develop quality measurement systems for the structure and process of health care delivery in both the inpatient and outpatient setting, several of which include care of patients with cerebrovascular disease. [5] [6] [7] [8] [9] The usefulness of these systems will depend largely on the validity and reliability of the measures chosen. Prior stroke quality improvement projects have chosen measures but have paid little attention to the measurement properties of the end points used. 10 -12 Poorly chosen measures in clinical trials have led to disastrous consequences, including patient harm, indecisive evidence, and wasted efforts. 13 Although this area has not been studied in detail, we have no reason to expect that choosing measures poorly in quality improvement projects will not result in similar consequences.
Given the effect that stroke has in both human and financial terms and the evidence that clinical practice often falls short of the ideal, the objective of this project is to develop a menu of valid and reliable performance measures for hospital-based, acute ischemic stroke care. We present here the methods of developing performance measures and the results of the expert panel's ratings for each measure along 6 dimensions.
Methods

Assembly of a National Panel
To assist in development and ranking of stroke performance measures, we convened a national panel composed of physicians, nurses, administrators, and advocacy representatives. We wanted to create a multiperspective panel of various stakeholders in the care of hospitalized stroke patients. We solicited nominations from 12 professional societies and organizations, including the American Academy of Family Physicians, the American Academy of Neurology, the American Association of Neuroscience Nurses, the American College of Emergency Physicians, the American College of Healthcare Executives, the American College of Physicians-American Society of Internal Medicine, the American Heart Association-American Stroke Association, the American Society for Neuroradiologists, the National Stroke Association, the Society of General Internal Medicine, and the VHA, Inc. From a list of 46 nominations, 16 individuals were selected on the basis of their field of expertise, geographic location, and time availability. The national panel included 2 stroke specialists, 2 general neurologists, 1 stroke rehabilitationist, 1 neuroradiologist, 1 emergency room physician, 2 internists, 1 family practitioner, 2 neuroscience nurses, 1 managed care organization director (who was also a family practitioner), 1 hospital association representative, and 2 stroke advocacy organization representatives (which included 1 patient representative). Names of the 16 panel members and their affiliated organizations are listed in Appendix 1.
Developing a List of Performance Measures
The research team generated an initial comprehensive list of potential measures and performed an on-site hospital "walk through" of a typical stroke patient's hospital experience. This list of performance measures was augmented by reviewing available clinical practice guidelines (see below) and performance measures used in published quality improvement projects involving the care of stroke patients. We also consulted the following sources: Health Plan Employer Data and Information set (HEDIS 3.0), 14 Computerized Needs-Oriented Quality Measurement Evaluation System (CONQUEST) 1.1, and the National Library of Healthcare Indicators performance measures. 15 The panel reviewed and focused the development of the performance measures during a half-day, face-to-face meeting in June 1999. From these deliberations, the research team developed 44 performance measures in 8 domains of acute stroke care. The draft performance measures underwent an external review by 3 content experts for wording clarity and specificity. Draft listing of the 44 performance measures is located in Table 1 . We focused primarily on process of care measures rather than on developing outcome measures. 5, 16 
Preparing Evidence Summaries for the Performance Measures
We developed evidence summaries for each of the draft performance measures. We used explicit search strategies to locate clinical practice guidelines, systematic reviews, randomized controlled trials, and cost-effectiveness analyses ( Table 2 ). The research team reviewed titles, abstracts, and articles from the literature identified. An article was accepted if the reviewer thought it provided evidence for a potential association between the process in question and better patient outcomes. We gave priority to literature that systematically identified and graded the quality of the evidence and that was issued by authoritative bodies (eg, guidelines and literature from specialty societies and government agencies).
We identified a total of 84 clinical practice guidelines, 68 systematic reviews, 11 narrative reviews, 52 randomized controlled trials, 6 cost-effectiveness analyses, and 18 other related studies. From this literature base, we prepared a detailed review of the evidence, linking each of the 44 draft performance measures to patient outcomes. In addition, we graded the level of evidence by use of criteria issued by the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. 17 A copy of the search strategies, literature identified, and evidence summaries is available from the corresponding author (R.G.H.) on request.
Dimensions of Quality Used to Rate Performance Measures
The panel rated each measure along 6 dimensions of quality: validity of evidence, feasibility of measurement, impact on outcomes, room for improvement, plausibility, and overall. These 6 dimensions of quality and the method of rating the performance measures within each dimension were adapted from 3 sources. The validity of evidence and the feasibility of measurement dimension were adapted from the Rand/UCLA appropriateness methodology as previously published. 18 Both of these measures were rated along a 9-point scale from a score of 1 (definitely not valid or feasible) to 9 (definitely valid or feasible). A measure was considered definitely valid if sufficient scientific evidence existed to support a link between performance of that measure and overall positive outcomes to patients. A measure was considered definitely feasible if information needed to assess adherence was thought to be available in the medical record or from patient or proxy surveys or interviews and likely to be accurate. The dimensions of room for improvement, plausibility, and impact on outcomes were adapted from the Harvard Q-SPAN-CD study, the goal of which was to identify a set of cardiovascular-related performance measures. 19 Each of these quality dimensions is rated along a 5-point scale. The room for improvement dimension asked panelists to rate each measure from a score of 1 (no room for improvement) to 5 (substantial room for improvement). The plausibility dimension asked panelists how plausible it was to expect that a quality improvement activity within a typical stroke care setting in the United States could improve adherence to the measure, from a score of 1 (not at all plausible) to 5 (extremely plausible). The impact on outcome dimension asked panelists to rate the measure as to the relative effect of outcome achieved if the measure is followed, from 1 (no impact) to 5 (very large impact). The final dimension was an overall rating of the utility of the measure in stroke quality-of-care assessment. This dimension was adapted from clinical audit criteria for monitoring patients with diabetes. 20 The 4 categories for rating the overall dimension were little reason to do, could do, should do, and must do.
Rating the Performance Measures
To rate the potential performance measures, we used a modified Delphi approach to achievement of consensus by combining evidence with expert judgment. 21 Two rounds of ratings were done, and the first round was done by mail. Each panelist received a copy of the evidence summaries and a measure-rating booklet; panelists had 3 weeks to rate each measure on the 6 dimensions. A copy of the measure-rating booklet is available from the corresponding author (R.G.H.) on request.
The second rating occurred during a face-to-face meeting November 9, 1999. Before this meeting, panelists received a summary of the results obtained from the first round of ratings. Patients admitted to hospital for an acute ischemic stroke should receive care within an organized stroke unit, which at a minimum should be defined as including multidisciplinary team care and nurses and physicians with special expertise in stroke, rehabilitation, or both.
Stroke unit A1
Stroke protocols
Patients admitted to a hospital with acute ischemic stroke should be managed with the aid of a stroke protocol (or critical care path, algorithm, or clinical pathway).
Stroke protocol C1
Domain II: Thrombolytic Management
Thrombolytic treatment
All patients who present to a hospital with an acute ischemic stroke should be evaluated for eligibility for rtPA and either offered rtPA or found to meet Ն1 of the exclusion criteria used in the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Trial.
rtPA treatment considered B2
For all acute ischemic stroke patients who receive rtPA, the American Heart Association Stroke Council/American Academy of Neurology thrombolysis protocol should be followed, including inclusion and exclusion criteria used in the NINDS trial.
rtPA treatment on protocol C1/C2
Time to treatment 80% of patients with an acute ischemic stroke who receive rtPA within 3 h of symptom onset should have rtPA administered within 1 h of hospital arrival.
rtPA within 3 h C1/C2
Patients who arrive at the hospital with an acute ischemic stroke with symptom onset of Յ3 h should be seen by a physician in the emergency room within 10 min.
ER physician within 10 min C1/C2
A physician with stroke expertise should be available within 15 min for patients who arrive at the hospital with an acute ischemic stroke with symptom onset of Յ3 h.
Stroke expert within 15 min C1/C2
Patients who arrive at hospital with an acute ischemic stroke with symptom onset of Յ3 h should have a head CT scan completed within 25 min.
Head CT done within 25 min C1/C2
Patients who arrive at the hospital with an acute ischemic stroke with symptom onset of Յ3 h should have their head CT scan interpreted within 45 min.
Head CT read within 45 min C1/C2
Patients with an acute ischemic stroke who receive rtPA should be in a monitored bed within Յ3 h of hospital arrival.
To bed within 3 h C1/C2
Transfer of patient For hospitals that do not administer rtPA, documentation should exist of discussions with family or other personnel regarding possible transfer of an rtPA-eligible patient to an institution that administers rtPA.
Transfer patient C1
Domain III: Emergent Evaluation of Acute Ischemic Stroke
Neurological assessment
All patients presenting with acute stroke symptoms should have a neurological assessment, including documentation in the medical record of a neurological history and examination.
Neurological assessment C1
Initial imaging studies All patients presenting with acute stroke symptoms should have a chest x-ray taken. Chest x-ray C2
All patients presenting with acute stroke symptoms should have serum glucose checked.
Serum glucose C2
All patients presenting with acute stroke symptoms should have serum electrolytes checked.
Serum electrolytes C2
All patients presenting with acute stroke symptoms should have CBC, including platelets, checked.
CBC, platelets C2
All patients presenting with acute stroke symptoms should have PT/PTT checked. PT/PTT C2 
Hypoxia
Every patient who presents with an acute stroke should have an evaluation for hypoxia (pulse oximetry or arterial blood gas determination).
Rule out hypoxia C1
Antihypertensive therapy
Orders for new antihypertensive agents should not be added within 24 hours of symptom onset unless any of the following is present: administration of thrombolytic therapy, SBP Ͼ220 mm Hg, DBP Ͼ120 mm Hg, MAP Ͼ130 mm Hg, worsening renal function, aortic dissection, myocardial infarction, congestive heart failure, or hypertensive encephalopathy.
Avoid BP therapy B2
Patients with acute ischemic stroke should not be given sublingual nifedipine for blood pressure management.
Avoid sublingual nifedipine C1
Treatment of fever
In patients with acute ischemic stroke who develop a fever (Ն38.5°C), the fever should be treated with antipyretics.
Treat fever C1
Documentation of stroke origin
All patients admitted with an acute ischemic stroke should have a presumed origin documented (cardioembolic, extracranial carotid, etc), or discussion of the differential diagnosis if the origin is not clear.
Document origin C1
Domain V: Medical Complication Prevention
Early mobilization
Patients with an acute ischemic stroke should be mobilized and out of bed (unless any of the following are present: coma, severe obtundation, progressing neurological signs or symptoms, severe orthostatic hypotension, acute myocardial infarction, or acute deep-vein thrombosis [until adequate anticoagulation has been achieved]).
within 24 h of stroke symptom onset Early mobilization: 24 h C1 within 48 h of stroke symptom onset Early mobilization: 48 h C1
Swallowing assessment
A screen for dysphagia (eg, simple water swallow test) should be performed on all acute ischemic stroke patients before they are given food or drink.
Swallow assessment: screen C1
Patients who fail a dysphagia screen should remain with no food or drink taken orally (NPO) and be evaluated by a speech or language therapist or other suitably trained person for a more detailed functional examination of swallow.
Swallow assessment: NPO and evaluation
C1
Urinary tract health Indwelling urethral catheters should be avoided unless absolutely indicated for strict fluid management, known prostate pathology, local urethral trauma, or wound care (eg, decubiti).
Avoid catheter C1
Insertion of indwelling urethral catheters should be avoided during thrombolytic infusion and for Ն30 minutes after infusion ends.
Avoid catheterization during rtPA
C1 Prophylaxis for DVT/PE
Patients with an acute ischemic stroke who have not received rtPA and who are nonambulatory should start receiving the following within the first 24 h of admission unless being treated concurrently with intravenous heparin or therapeutic warfarin.
Low-dose unfractionated heparin, low-molecular-weight heparin, or heparinoids DVT/PE: heparins B2
Intermittent pneumatic compression stockings DVT/PE: stockings B1
Low-dose unfractionated heparin, low-molecular-weight heparin, heparinoids, or intermittent pneumatic compression stockings DVT/PE: both B1/B2
Patients with an acute ischemic stroke who have received rtPA and who are nonambulatory should start receiving the following 24 h to 48 h after rtPA administration unless concurrent treatment with intravenous heparin or therapeutic warfarin occurs.
Low-dose unfractionated heparin, low-molecular-weight heparin, or heparinoids DVT/PE: heparins (rtPA) C2
Intermittent pneumatic compression stockings DVT/PE: stockings (rtPA) C2
Low-dose unfractionated heparin, low-molecular-weight heparin, heparinoids, or intermittent pneumatic compression stockings DVT/PE: both (rtPA) C2
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For each measure and each quality dimension, the panelists received an anonymous distribution of the ratings of the other panelists in addition to a notation of their own ratings. Therefore, 16 unique summary tables were prepared (1 for each panel member). A structured approach was followed during the face-to-face meeting, during which the panelists rerated each of the performance measures. First, the measure was read aloud to the panel. Second, the panel discussed the wording of the measure and any wording changes necessary to improve its clarity and specificity. Third, the meeting comoderators (R.G.H. and B.G.V.) initiated a discussion about the measure, summarizing to the group the distribution of responses across the quality dimensions. The comoderators attempted to limit the role of dominant members and encourage the participation of all panel members. Fourth, once a discussion of a measure was complete, the process was repeated for each measure in a particular domain of care, and the panel rerated the performance measures. This process was repeated until all performance measures were rerated. The wording of 7 performance measures changed on the basis of discussion during the meeting.
Analysis
For each of the 44 performance measures in each of the 6 quality dimensions, we present the frequency of panel responses. For each domain, we highlight those measures for which Ն75% of the panel members (Ն12) rated higher than a cutoff score set by the research team and consider these measures highly rated. For the overall dimension, we considered measures highly rated if Ն12 of the 16 panel members ranked the measure should or must do. For the validity and feasibility dimension, we considered the measures highly rated if Ն12 of the 16 panel members rated the measure 7, 8, or 9. For the impact on outcomes, room for improvement, and plausibility dimension, we consider measures highly rated if Ն12 of the 16 panel members ranked the measure 4 or 5. In addition, we present the mean and median score for each measure and rank order the measures by mean scores. To quantify the amount of variability for the rating of each performance measure, we present the SD. The smaller the SD, the more homogenous the observations. Because the observations are, in fact, panel-member ratings, the SD can be interpreted as a measure of agreement. Using Spearman rank correlation coefficients, we assessed the association among the individual median ratings for each quality dimension. We also present the ratings on the overall quality dimension on the basis of whether the panelist was a neurologist (nϭ5) or a nonneurologist (nϭ11). We compared the responses of neurologist with nonneurologist on the overall rating using the Wilcoxon rank test. Patients with an acute ischemic stroke in the anterior curculation should undergo noninvasive carotid artery imaging during hospitalization unless the medical record documents, in the same time period, that the patient is not a candidate for carotid surgery or that carotid artery imaging will be performed on an outpatient basis.
Carotid imaging C1
Domain VII: Secondary Prevention
Acute aspirin therapy
Patients with an acute ischemic stroke who are not on intravenous heparin, low molecular-weight heparin, heparinoids, or warfarin should receive an antiplatelet agent within 48 h of stroke onset unless contraindicated. (Patients who received rtPA cannot receive an antiplatelet agent in the first 24 h.
Acute aspirin B2
Antithrombotic therapy on discharge
Patients with acute ischemic stroke should be discharged on antithrombotic therapy (eg, aspirin, ticlopidine, clopidogrel, dipyridamole, and warfarin) unless contraindicated.
Antithrombotics on hospital discharge
A1 Warfarin in atrial fibrillation
Patients with acute ischemic stroke and nonvalvular atrial fibrillation should be discharged on warfarin unless contraindicated Warfarin in atrial fibrillation A1
Smoking Cessation
If a patient is admitted to hospital with an acute ischemic stroke, smoking status should be assessed, and in smoking patients cessation counseling should be initiated or reinforced.
Smoking cessation C1
Domain VIII: Nontechnical Aspects of Care
Patient and caregiver education and support
Before discharge from hospital after acute ischemic stroke, a stroke caregiver, the patient, or both should receive education about stroke (ie, cause, treatment, risk-factor modification, and other topics) and should be given information about resources for social support or services.
Education/support B1 
Results
Overall Dimension
Of the 16 panelists, Ն12 rated 21 of the 44 measures either should or must do (Table 3 ). The 2 most highly rated performance measures with the most agreement were warfarin in atrial fibrillation and antithrombotics on hospital discharge. The carotid imaging and stroke unit performance measures also were rated highly, with tight agreement. The recombinant tissue plasminogen activator (rtPA) treatment considered and rtPA treatment on protocol performance measures were more highly rated than the rtPA within 3 hours measure, but the rtPA within 3 hours measure lacked agreement with a spread of responses and an SD that is 37th widest (1.1) of the 44 performance measures. Two performance measures were notable for the amount of rating agreement: DVT/PE: heparins and stroke protocol. The stroke protocol measure was not highly rated, with a mean score that ranked 27th of 44, but it had an agreement rank based on its SD of 4 (0.5). All panel members ranked the acute aspirin measure as either must or should do except 1, who ranked the measure as little reason to do. The 2 acute diagnostic tests that ranked most highly were the serum glucose and ECG performance measures. Notably, 19 performance measures ranked higher than the avoid sublingual nifedipine measure in the overall ratings. The initial imaging performance measures ranked very low on the list, as did most of the time-totreatment thrombolytic performance measures.
Validity Dimension
As shown in Table 4 , Ն12 panelists highly rated (7, 8, or 9) 8 performance measures. The warfarin in atrial fibrillation and antithrombotics on hospital discharge had the highest validity ratings with the most agreement. The stroke unit and acute aspirin measures also were rated highly. Panel members often rated the validity of the scientific evidence higher than the level of evidence provided by the research team (Table 3) . For example, of the 8 highly rated measures, 3 had A-level evidence, 2 had B-level evidence, and 3 had C-level evidence (see Table 2 for further information on evidence level 17 ).
Feasibility Dimension
Feasibility ratings were rated more highly than validity ratings, and most of the measures (38 of 44) were rated 7, 8, or 9 ( Table 5 ). Many of the early diagnostic-test performance measures were rated highly, including serum glucose, complete blood count (CBC), platelets, prothrombin time/partial thromboplastin time (PT/PTT), and serum electrolytes, as was warfarin in atrial fibrillation. Performance measures that ranked lower on the list included the time-to-thrombolytic measures (eg, measures ranked relatively low on the feasibility ratings included stroke expert within 15 minutes, head CT read within 45 minutes, and to bed within 3 hours).
Impact on Outcomes Dimension
Only 3 impact on outcome measures were rated highly: warfarin in atrial fibrillation, antithrombotics on hospital discharge, and stroke unit (Table 6 ). Panelists felt that the 2 swallow assessment performance measures had larger impact on patient outcomes than the mobilization and rtPA measures.
Room for Improvement Dimension
Eighteen measures were highly rated; the highest was stroke unit (Table 7) . Many of the time-to-thrombolytic treatment performance measures, such as head CT done within 25 minutes, rtPA within 3 hours, stroke expert within 15 minutes, and head CT read within 45 minutes, also were rated highly. The education/support measure also was thought to need much or substantial improvement. In addition, many of the highly feasibly ranked performance measures were at the lower end of the rankings in the room for improvement dimension (eg, glucose, CBC, platelets, and PT/PTT.
Plausibility Dimension
Nine of the measures were rated highly on the plausibility dimension, including 3 that would require substantial changes in the infrastructure of stroke care delivery: stroke unit, rtPA considered, and head CT done within 25 minutes (Table 8) .
Relationships Among Dimensions
Pairwise correlations of medians for validity, impact on outcomes, room for improvement, plausibility, and the overall rating ranged from 0.43 to 0.82 (all PϽ0.004). Feasibility ratings were not correlated with any other dimension except for a negative correlation with room for improvement (Ϫ0.5, Pϭ0.0001).
Neurologists Versus Nonneurologists
Neurologists tended to rate the overall quality dimension lower than the nonneurologists (PϽ0.01, Table 9 ). Two performance measures that the neurologists rated higher than the nonneurologists were avoid blood pressure (BP) therapy and DVT/PE: heparins. The neurologists rated all of the measures relating to thrombolytic management lower on the overall dimension compared with the nonneurologists. Neurologists also were more inclined to give lower ratings to the swallow assessment performance measures and the smoking cessation measure compared with the nonneurologists.
Discussion
The rationale for developing stroke performance measures is to promote performance excellence and to improve quality of care. Performance excellence in health care requires that performance results are measured, trended, and compared with prior performance or best in industry and that best practices are deployed and aligned in a practice or on an organization-wide basis. The goal of a structured approach to performance improvement built around cycles of learning is to deliver ever-improving value to patients while at the same time maximizing the overall practice performance and capabilities. A stroke care self-assessment is important because one can gain self-knowledge and identify opportunities for improvement. In addition, a standard set of core stroke measures can facilitate a common language that promotes benchmarking and sharing of best practices. Ultimately, the best set of stroke performance measures may be a flexible menu of performance measures, adaptable to the needs of each provider, stroke team, or organization. An increasing number of quality-improvement initiatives exist both in the public and private sectors that could benefit from a standard menu of stroke performance measures. The present study reveals 21 performance measures rated highly by our definition (ie, 75% of panelists rated should or must do) for hospitalized patients with acute ischemic stroke. The 2 most highly rated and agreed-on performance measures for the overall quality dimension in the present study are 2 of the 3 performance measures being used by the Health Care Financing Administration (HCFA) to create a monitoring system that supports quality improvement for fee-for-service Medicare beneficiaries (warfarin in atrial fibrillation and antithrombotics on hospital discharge). 5 The third measure (avoid sublingual nifedipine) being used by HCFA in their qualitymonitoring program was in the highly rated group, but 19 measures ranked higher. In addition, the measure that ranked third on the overall dimension in our analysis (carotid imaging) is similar to 1 of 3 stroke performance measures used in a study of Medicare claims data to measure underuse. 8 Finally, in a recently published conference proceeding on measurement and improvement of quality of stroke care, several structure and process measures were recommended. 22 Several of their recommendations received high ratings on the overall dimension in the present study (antithrombotics on hospital discharge and warfarin in atrial fibrillation), whereas others did not (initial imaging: 24 hours and treat fever).
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No standard method exists for developing, rating, and analyzing the results of performance measure ratings, and several methods have been used. 19, [23] [24] [25] We used an explicit modified-Delphi consensus method to combine evidence with expert judgment, a method being used more frequently in health care research. 21 No attempt was made to "force" consensus, and what we attempted to achieve was the best possible consensus on a given date, with a given amount of evidence, with a particular composition of panel members. We assembled a multidisciplinary panel with broad US representation and stroke care perspectives. The modified-Delphi approach has limitations and theoretically can represent a collective error in judgment or inference and can be influenced by panel composition. For example, prior research has shown that multispecialty panel ratings are more divergent than single specialty panels. 26 However, we believe that a rigorously applied method and prudent exercise of inference and common sense in the face of incomplete evidence is an integral and necessary component for developing valid performance measures, particularly in highly prevalent conditions.
In addition, we present all of the data including the mean, median, and SD, recognizing the potential limitation of nonnormality. Both the absolute score and the distribution of responses are important when evaluating the rating results of the performance measures. For example, for the overall rating, the stroke protocol measure had a relatively low absolute score (mean 2.7, median 3.0), but tight agreement existed, as evidenced by the distribution of responses (SD 0.5). In contrast, the rtPA within 3 hours measure had a much higher absolute score (mean 3.2, median 4.0) but much less panel agreement (SD 1.1) . Disagreed-on performance measures may be more difficult to implement and monitor despite ardent support by a majority.
Seven of the 18 highly rated measures on the room for improvement dimension were for the thrombolytic performance measures. However, despite this perceived need for room for improvement, many of the thrombolytic performance measures received low scores on the overall ratings, particularly the time-to-treatment measures. This may be explained in part by the relative disagreement demonstrated for most of the thrombolytic measures. Also, neurologists rated all 9 performance measures pertaining to thrombolytic management lower than did the nonneurologists on the overall quality dimension, a surprising finding given that other panel ratings have found that those who use a particular technology tend to rate higher than those who do not. 26 This may reflect the particular bias of the neurologists on the panel in that only 2 were stroke specialists.
The present study also addresses an area of difficulty in the field of quality measurement and improvement. We found a negative correlation on the measure ratings between room for improvement and feasibility ratings, which indicates that those performance measures thought to be in the need of most improvement were the most difficult to collect. This negative correlation again emphasizes the limits of the currently available data sources, primarily administrative data and the medical record, for quality-ofcare assessment, and the need to develop new methods of information retrieval and tracking.
Of 44 potential performance measures in the present study, only 3 were graded as having A-level evidence, whereas most of the performance measures (34 of 44) had C-level evidence. The present study highlights the lack of research evidence for most of what we do for hospitalized patients with ischemic stroke and that we cannot expect clear verdicts from randomized controlled trials with sufficient statistical precision to address most of our processes of care. These occurrences also probably explain the lack of overall panel agreement for rating the quality dimensions. However, despite the lack of research evidence to support the performance measures, many panelists rated the validity of the evidence as relatively strong. In addition, most of the panelists thought that quality-ofcare assessment should or must be performed on 21 of the measures, despite a paucity of evidence to support a link between the measure and patient outcomes for most of them.
What are the implications of this research for performance improvement activities? For local efforts, individ-ual hospitals or stroke programs may want to review the list of highly rated indicators and focus on measuring, trending, and improving adherence to Ն1 of the performance measures. Selection of the measures should be guided by local perceived need, availability of resources, comprehensiveness of services, and relative ranking of the measures on the dimensions of quality. Keep in mind that most of these performance measures have not been tested yet in terms of reliability. The validity of a stroke performance measure is necessary but not sufficient for quality-of-care purposes, and a validated measure can be made invalid if not reliably collected. 27 Therefore, a local program interested in measuring and tracking patient performance on prophylaxis for deep-vein thrombosis and pulmonary embolism (DVT/PE), for example, must be confident that data can be accurately collected. The issue is no different for national quality-improvement initiatives, for which states, providers, hospitals, or health systems may be held accountable in terms of having their adherence rates made public. However, under such circumstances, the reliability of the performance measures must be established before the data are measured and reported on. We know from a recent study that 3 performance measures (warfarin in atrial fibrillation, antithrombotics on hospital discharge, and avoid sublingual nifedipine) had excellent interrater reliabilities with trained abstractors. 5 More research is needed to assess the reliability of collected data for other performance measures, and the results from the present study can guide the selection of what measures to test by focusing on those measures that were rated highly.
Other areas also are in need of future research. Continued development and testing is needed of ischemic stroke measures for care before and after hospitalization and for patients with transient ischemic attacks, intracerebral hemorrhages, and subarachnoid hemorrhages. More research is needed on exploiting existing data sources and unearthing relevant data about quality, but this is not enough. We need to harness the potential of information technology for quality improvement by developing new systems of data collection that will provide us with additional opportunities to track, trend, and compare stroke performance measures. Finally, the lack of scientific data to support what we do for patients is startling, and major new investments in studies to establish links between process and outcomes of care would provide better information for decision making.
Given the burden of stroke in terms of suffering and cost, the evidence that practice often falls short of the ideal and the desire to go beyond conformance to standard to focus on excellence, we have developed potential performance measures for hospitalized patients with acute ischemic stroke ultimately to be used in national and local initiatives to improve quality of stroke care. By such efforts we will begin to narrow the evidence-practice gap and truly give stroke patients precisely what they need and want, precisely when they need and want it.
would appeal to a wide audience. While experts may disagree on the relative order of importance of targets, and external validation of these results by other groups with different compositions (eg, single-specialty) would raise content validity, few would dispute the main findings of the panel. The application of their findings will depend on the local structure of stroke care delivery.
This process underscored the lack of definitive (grade A) evidence of efficacy for the majority of stroke-care interventions (evidence-to-practice gap) and the lack of evidence to demonstrate effective care where efficacy has been shown (practice-to-evidence gap). Clinical stroke and health service researchers have both a blank slate and an unobscured list of proofs to provide. Administrators and all health professionals who care for stroke patients have been given targets. Holloway et al have issued a challenge.
